Results 61 to 70 of about 479 (148)

Options for combination therapy of influenza and ARVI with combined drugs

open access: yesМедицинский совет, 2015
According to the World Health Organization (WHO), 3 to 5 million cases of influenza are registered every year worldwide, of which 250--500 thousand are fatal.
T. V. Sologub   +2 more
doaj   +1 more source

Клинико-эпидемиологическая характеристика гриппа в период сезонного подъема весной 2015 года

open access: yes, 2016
Грипп и гриппоподобные заболевания являются одной из актуальных медицинских и социальных проблем современного общества в силу высокой заболеваемости, риска развития тяжелых осложнений, По данным ВОЗ гриппом ежегодно заболевают десятки тысяч человек.
Нюганен Анна Олеговна   +1 more
core  

Adequate therapy of acute respiratory infections and flu

open access: yesМедицинский совет, 2015
Acute respiratory infections (ARVI) including flu are the most widespread pathologies in the structure of children's infectious diseases [1]. The article tells about the main causative agents of ARVI in children, the clinical patterns of ARVI and flu ...
E. M. Ovsyannikova   +4 more
doaj   +1 more source

Вирус гриппа птиц, его особенности и распространение в природе [PDF]

open access: yes, 2010
птицы, грипп птиц, контагиозная болезнь, ортомиксовирус, высоковирулентные вирусы, низковирулентные ...
Минчук, Ю. Н.
core  

Molnupiravir in the treatment of patients with influenza or acute respiratory viral infections: a multicenter comparative randomized double-blind placebo-controlled trial

open access: yesФармация и фармакология (Пятигорск)
The aim. To evaluate the efficacy and safety of molnupiravir compared to placebo in patients with influenza and/or ARVI.Materials and methods. The study involved 300 patients.
O. M. Drapkina   +19 more
doaj   +1 more source

ПРЕИМУЩЕСТВА ПРИМЕНЕНИЯ ЭРГОФЕРОНА И АНАФЕРОНА В ПРОФИЛАКТИКЕ И ЛЕЧЕНИИ ОРВИ И ГРИППА

open access: yesАрхивъ внутренней медицины, 2015
Эргоферон и Анаферон относятся к противовирусным препаратам нового поколения и принадлежат к группе ИИ. Анаферон и Эргоферон содержат антитела к ИФН-γ в так называемой релиз-активной форме.

doaj   +1 more source

Грипп, острые респираторные вирусные инфекции (ОРВИ) и тяжёлые острые респираторные инфекции (ТОРИ) в Республике Молдова в 2013- 2014 сезоне: меры контроля и ответа [PDF]

open access: yes, 2014
Centrul Național de Sănătate Publică, Chișinău, Conferința științifico-practică cu participare internațională Centrul de Sănătate Publică din municipiul Chișinău – 70 de ani la straja sănătăţii 23 octombrie 2014This paper contains the results of ...
Cojocaru, Radu   +6 more
core   +1 more source

Assessment of Population Immunity to Influenza and Acute Respiratory Viral Infections of Moscow Population during 2023–2024 Epidemic Season

open access: yesЭпидемиология и вакцинопрофилактика
Relevance. Acute respiratory viral infections (ARVI) annually occupy leading positions in terms of morbidity and economic damage both in the world and in the Russian Federation. From an epidemiological point of view, it is important to constantly monitor
V. A. Gushchin   +10 more
doaj   +1 more source

Assessment of the Costs Associated with Outpatient and Inpatient Treatment of ARVI and Influenza and its Complications

open access: yesЭпидемиология и вакцинопрофилактика, 2015
In this paper the authors are presenting the analysis of an economic burden caused by influenza and acute respiratory viral infections (ARVI). This is the first study of its kind in the Kyrgyz Republic. The goal of the study was to calculate the economic
Z. Sh. Nurmatov
doaj   +1 more source

Cyclamen europaeum (Cyclamen purpurascens) extract as adjuvant for nasal immunization of mice with influenza antigens

open access: yesБиопрепараты: Профилактика, диагностика, лечение, 2018
The article describes the first attempt to use the juice and extract of Cyclamen europaeum (Cyclamen purpurascens) tubers as an adjuvant for intranasal immunization of mice with influenza antigens.
A. S. Gudymo   +6 more
doaj  

Home - About - Disclaimer - Privacy